TW202028179A - 胺基酸化合物及使用方法 - Google Patents
胺基酸化合物及使用方法 Download PDFInfo
- Publication number
- TW202028179A TW202028179A TW108136254A TW108136254A TW202028179A TW 202028179 A TW202028179 A TW 202028179A TW 108136254 A TW108136254 A TW 108136254A TW 108136254 A TW108136254 A TW 108136254A TW 202028179 A TW202028179 A TW 202028179A
- Authority
- TW
- Taiwan
- Prior art keywords
- tetrahydro
- naphthyridin
- ethyl
- homoserine
- cyclobutyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 512
- -1 Amino acid compounds Chemical class 0.000 title claims description 306
- 150000001875 compounds Chemical class 0.000 claims abstract description 807
- 150000003839 salts Chemical class 0.000 claims abstract description 334
- 108010044426 integrins Proteins 0.000 claims abstract description 148
- 102000006495 integrins Human genes 0.000 claims abstract description 148
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims abstract description 36
- 206010016654 Fibrosis Diseases 0.000 claims abstract description 34
- 230000004761 fibrosis Effects 0.000 claims abstract description 33
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims abstract description 27
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 25
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims abstract description 22
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 claims description 291
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 claims description 229
- 229910052736 halogen Inorganic materials 0.000 claims description 178
- 150000002367 halogens Chemical class 0.000 claims description 145
- 125000001072 heteroaryl group Chemical group 0.000 claims description 135
- 125000000623 heterocyclic group Chemical group 0.000 claims description 95
- 125000003118 aryl group Chemical group 0.000 claims description 92
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 83
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 82
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 81
- 201000010099 disease Diseases 0.000 claims description 81
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 79
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 79
- 229910052805 deuterium Inorganic materials 0.000 claims description 79
- 230000003176 fibrotic effect Effects 0.000 claims description 62
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 51
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 47
- 125000005843 halogen group Chemical group 0.000 claims description 47
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 47
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 46
- 229910052739 hydrogen Inorganic materials 0.000 claims description 44
- 239000002253 acid Substances 0.000 claims description 41
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 40
- 230000002401 inhibitory effect Effects 0.000 claims description 39
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 37
- 125000000217 alkyl group Chemical group 0.000 claims description 35
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 35
- 210000001519 tissue Anatomy 0.000 claims description 35
- 239000001257 hydrogen Substances 0.000 claims description 34
- 150000001413 amino acids Chemical class 0.000 claims description 32
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 32
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 31
- 125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 claims description 29
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 25
- 229910052799 carbon Inorganic materials 0.000 claims description 24
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 23
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 23
- 150000002431 hydrogen Chemical class 0.000 claims description 22
- 210000004027 cell Anatomy 0.000 claims description 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 21
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 18
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 16
- 125000004076 pyridyl group Chemical group 0.000 claims description 16
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 15
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 15
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 15
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 15
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 15
- 230000004913 activation Effects 0.000 claims description 14
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 14
- 210000004072 lung Anatomy 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 13
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 13
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 13
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 12
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 12
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 12
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 11
- 125000002947 alkylene group Chemical group 0.000 claims description 11
- 208000020832 chronic kidney disease Diseases 0.000 claims description 11
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 11
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims description 11
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 10
- 206010039710 Scleroderma Diseases 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 10
- 208000011231 Crohn disease Diseases 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 125000002393 azetidinyl group Chemical group 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 230000002496 gastric effect Effects 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 125000004429 atom Chemical group 0.000 claims description 8
- 210000000013 bile duct Anatomy 0.000 claims description 8
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 6
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 6
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 6
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 claims description 6
- 230000005855 radiation Effects 0.000 claims description 6
- 206010023421 Kidney fibrosis Diseases 0.000 claims description 5
- 230000009787 cardiac fibrosis Effects 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 125000003566 oxetanyl group Chemical group 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 206010004664 Biliary fibrosis Diseases 0.000 claims description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 4
- 206010050207 Skin fibrosis Diseases 0.000 claims description 4
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 claims description 4
- 210000002919 epithelial cell Anatomy 0.000 claims description 4
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 claims description 4
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 125000006085 pyrrolopyridyl group Chemical group 0.000 claims description 4
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 3
- URUKMUHHWWCNKS-UHFFFAOYSA-N 2-cyclohexyloxane Chemical compound C1CCCCC1C1OCCCC1 URUKMUHHWWCNKS-UHFFFAOYSA-N 0.000 claims description 3
- PZTRNMQIYAZMCX-UHFFFAOYSA-N 2-cyclooctyloxocane Chemical group C1CCCCCCC1C1OCCCCCC1 PZTRNMQIYAZMCX-UHFFFAOYSA-N 0.000 claims description 3
- 206010010317 Congenital absence of bile ducts Diseases 0.000 claims description 3
- 201000005271 biliary atresia Diseases 0.000 claims description 3
- 125000004744 butyloxycarbonyl group Chemical group 0.000 claims description 3
- 210000002950 fibroblast Anatomy 0.000 claims description 3
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 claims description 3
- 210000000232 gallbladder Anatomy 0.000 claims description 3
- 210000005003 heart tissue Anatomy 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 210000005228 liver tissue Anatomy 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 210000005084 renal tissue Anatomy 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 claims description 3
- BULPNSGUAZZZCF-PLYFQIMLSA-N (2S)-2-(4,5,6,7-tetrahydro-1H-indazole-7-carbonylamino)-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound N1=C(C=CC=2CCCNC1=2)CCC1CC(C1)OCC[C@H](NC(=O)C1CCCC=2C=NNC1=2)C(=O)O BULPNSGUAZZZCF-PLYFQIMLSA-N 0.000 claims description 2
- ZYFFBSMCHLIDHV-UYJHFMRCSA-N (2S)-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxy-2-[(1,1,1-trifluoro-2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound N1=C(C=CC=2CCCNC1=2)CCC1CC(C1)OCC[C@H](NC(=O)OC(C(F)(F)F)(C)C)C(=O)O ZYFFBSMCHLIDHV-UYJHFMRCSA-N 0.000 claims description 2
- YUAWJDYPCCAFGV-UDJZJCJKSA-N (2S)-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxy-2-[(2,4,6-trimethylpyrimidine-5-carbonyl)amino]butanoic acid Chemical compound N1=C(C=CC=2CCCNC1=2)CCC1CC(C1)OCC[C@H](NC(=O)C=1C(=NC(=NC=1C)C)C)C(=O)O YUAWJDYPCCAFGV-UDJZJCJKSA-N 0.000 claims description 2
- DGRBCGJJVUNTFQ-WQMGSUCASA-N (2S)-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxy-2-[[1-[3-(trifluoromethoxy)phenyl]cyclopropanecarbonyl]amino]butanoic acid Chemical compound N1=C(C=CC=2CCCNC1=2)CCC1CC(C1)OCC[C@H](NC(=O)C1(CC1)C1=CC(=CC=C1)OC(F)(F)F)C(=O)O DGRBCGJJVUNTFQ-WQMGSUCASA-N 0.000 claims description 2
- NBUHEBZCMGQXGW-UHFFFAOYSA-N 2-(2-ethylbutanoylamino)-6-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]hexanoic acid Chemical compound C(C)C(C(=O)NC(C(=O)O)CCCCOCCC1=NC=2NCCCC=2C=C1)CC NBUHEBZCMGQXGW-UHFFFAOYSA-N 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- GDSQTWDUCDSZEY-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-indazole Chemical group C1CCCC2=C1C=NN2 GDSQTWDUCDSZEY-UHFFFAOYSA-N 0.000 claims description 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 2
- 125000006164 6-membered heteroaryl group Chemical group 0.000 claims description 2
- 208000024985 Alport syndrome Diseases 0.000 claims description 2
- OIWOCFOJDONMTF-GQOXECLESA-N C(#N)CC(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C Chemical compound C(#N)CC(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C OIWOCFOJDONMTF-GQOXECLESA-N 0.000 claims description 2
- LKLBOTZGAZOMCD-JITJBCMDSA-N C(C)(=O)N1CC(C1)(C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(=O)N1CC(C1)(C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 LKLBOTZGAZOMCD-JITJBCMDSA-N 0.000 claims description 2
- MUBOCXVSBAJANH-BZCIDDNGSA-N C(C)(=O)NCC(C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(=O)NCC(C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 MUBOCXVSBAJANH-BZCIDDNGSA-N 0.000 claims description 2
- VOVWQSSPALFHDP-FNEQHPHYSA-N C(C)(C)(C)C1=CC(=NC(=N1)C1=CC=CC=C1)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)(C)C1=CC(=NC(=N1)C1=CC=CC=C1)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 VOVWQSSPALFHDP-FNEQHPHYSA-N 0.000 claims description 2
- QBTAANARAWHSQC-UDJZJCJKSA-N C(C)C1(CCC(CC1)(F)F)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)C1(CCC(CC1)(F)F)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 QBTAANARAWHSQC-UDJZJCJKSA-N 0.000 claims description 2
- CBILFTGRPMBJNY-MTQWGCILSA-N CC(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(CC1=CC=CC=C1)C Chemical compound CC(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(CC1=CC=CC=C1)C CBILFTGRPMBJNY-MTQWGCILSA-N 0.000 claims description 2
- DMBMKRSKYQFQOU-GQOXECLESA-N CC(CC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)C Chemical compound CC(CC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)C DMBMKRSKYQFQOU-GQOXECLESA-N 0.000 claims description 2
- VIJNSDBCMJRPCN-GQOXECLESA-N CC1(CN(C1)S(=O)(=O)C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CC1(CN(C1)S(=O)(=O)C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 VIJNSDBCMJRPCN-GQOXECLESA-N 0.000 claims description 2
- IOVJAXHVQIGGLL-OFWQUVEVSA-N CC1=NN(C(=C1)C)C1C(CCCC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CC1=NN(C(=C1)C)C1C(CCCC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 IOVJAXHVQIGGLL-OFWQUVEVSA-N 0.000 claims description 2
- CTLUQNIUBWNIMI-YMPVSJOXSA-N CS(=O)(=O)N1CC(CCC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CS(=O)(=O)N1CC(CCC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 CTLUQNIUBWNIMI-YMPVSJOXSA-N 0.000 claims description 2
- GZGQFDYXPIMJJH-DLUKIOLESA-N FC1=C(C=CC=C1)C1(CC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound FC1=C(C=CC=C1)C1(CC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 GZGQFDYXPIMJJH-DLUKIOLESA-N 0.000 claims description 2
- ZERWGBHYOAOFGK-BGERDNNASA-N OC(C(=O)ON([C@@H](CCO)C(=O)O)CCCCC1=NC=2NCCCC=2C=C1)C1=CC=CC=C1 Chemical compound OC(C(=O)ON([C@@H](CCO)C(=O)O)CCCCC1=NC=2NCCCC=2C=C1)C1=CC=CC=C1 ZERWGBHYOAOFGK-BGERDNNASA-N 0.000 claims description 2
- OGSHYTYJGZHOPP-UDJZJCJKSA-N OCC[C@@H](C(O)=O)N(C1CC(CCC2=NC(NCCC3)=C3C=C2)C1)OCC1=CC=NC=C1 Chemical compound OCC[C@@H](C(O)=O)N(C1CC(CCC2=NC(NCCC3)=C3C=C2)C1)OCC1=CC=NC=C1 OGSHYTYJGZHOPP-UDJZJCJKSA-N 0.000 claims description 2
- 150000001555 benzenes Chemical group 0.000 claims description 2
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims description 2
- 208000003215 hereditary nephritis Diseases 0.000 claims description 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 2
- DASPXDAOECXGLI-SISMUFEVSA-N (2S)-2-(4,5,6,7-tetrahydro-1H-indazole-6-carbonylamino)-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound N1=C(C=CC=2CCCNC1=2)CCC1CC(C1)OCC[C@H](NC(=O)C1CCC=2C=NNC=2C1)C(=O)O DASPXDAOECXGLI-SISMUFEVSA-N 0.000 claims 1
- HTOWTDPFDXQLCY-SVIIMATRSA-N (2S)-2-(5,6,7,8-tetrahydronaphthalene-1-carbonylamino)-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound N1=C(C=CC=2CCCNC1=2)CCC1CC(C1)OCC[C@H](NC(=O)C1=CC=CC=2CCCCC1=2)C(=O)O HTOWTDPFDXQLCY-SVIIMATRSA-N 0.000 claims 1
- VXJZZVJKVRXUJG-DEOSSOPVSA-N (2S)-2-(5,6,7,8-tetrahydronaphthalene-1-carbonylamino)-4-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy]butanoic acid Chemical compound N1=C(C=CC=2CCCNC1=2)CCCCOCC[C@H](NC(=O)C1=CC=CC=2CCCCC1=2)C(=O)O VXJZZVJKVRXUJG-DEOSSOPVSA-N 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- VSMAWKFGJPMWAT-UHFFFAOYSA-N 2-(2-phenylpropanoylamino)-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound C1(=CC=CC=C1)C(C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1)C VSMAWKFGJPMWAT-UHFFFAOYSA-N 0.000 claims 1
- PFXQOSXLXHIHFO-UHFFFAOYSA-N 2-(3,3-dimethylbutanoylamino)-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound CC(CC(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C PFXQOSXLXHIHFO-UHFFFAOYSA-N 0.000 claims 1
- XOFKUKVGCUQGHA-UHFFFAOYSA-N 2-(3,4,5,6,7,7a-hexahydro-2H-1-benzofuran-3a-carbonylamino)-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound O1CCC2(C1CCCC2)C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1 XOFKUKVGCUQGHA-UHFFFAOYSA-N 0.000 claims 1
- MOIDYRBVDBEGGG-UHFFFAOYSA-N 2-(pyrimidin-4-ylamino)-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy]pentanoic acid Chemical compound N1=CN=C(C=C1)NC(C(=O)O)CCCOCCCC1=NC=2NCCCC=2C=C1 MOIDYRBVDBEGGG-UHFFFAOYSA-N 0.000 claims 1
- DDAMGDFYVCARKH-UHFFFAOYSA-N 2-[(1-cyclopropylcyclopropanecarbonyl)amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound C1(CC1)C1(CC1)C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1 DDAMGDFYVCARKH-UHFFFAOYSA-N 0.000 claims 1
- QRLBGUXTMDORFW-UHFFFAOYSA-N 2-[(1-methylindazole-4-carbonyl)amino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy]pentanoic acid Chemical compound CN1N=CC=2C(=CC=CC1=2)C(=O)NC(C(=O)O)CCCOCCCC1=NC=2NCCCC=2C=C1 QRLBGUXTMDORFW-UHFFFAOYSA-N 0.000 claims 1
- NMAYEJUARMKEBE-UHFFFAOYSA-N 2-[(1-methylindazole-4-carbonyl)amino]-6-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]hexanoic acid Chemical compound CN1N=CC=2C(=CC=CC1=2)C(=O)NC(C(=O)O)CCCCOCCC1=NC=2NCCCC=2C=C1 NMAYEJUARMKEBE-UHFFFAOYSA-N 0.000 claims 1
- VEIIQZKYUXJFDB-UHFFFAOYSA-N 2-[(2,4-dimethylpyridine-3-carbonyl)amino]-4-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy]butanoic acid Chemical compound CC1=NC=CC(=C1C(=O)NC(C(=O)O)CCOCCCCC1=NC=2NCCCC=2C=C1)C VEIIQZKYUXJFDB-UHFFFAOYSA-N 0.000 claims 1
- KHIIFNJWHRXDDA-UHFFFAOYSA-N 2-[(2-hydroxy-1,3-dihydroindene-2-carbonyl)amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound OC1(CC2=CC=CC=C2C1)C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1 KHIIFNJWHRXDDA-UHFFFAOYSA-N 0.000 claims 1
- XQNZWCJSKNDUJC-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy]pentanoic acid Chemical compound C(C)(C)(C)OC(=O)NC(C(=O)O)CCCOCCCC1=NC=2NCCCC=2C=C1 XQNZWCJSKNDUJC-UHFFFAOYSA-N 0.000 claims 1
- KOENVOLWGFUKFS-UHFFFAOYSA-N 2-[(2-phenylacetyl)amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound C1(=CC=CC=C1)CC(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1 KOENVOLWGFUKFS-UHFFFAOYSA-N 0.000 claims 1
- JNVPABCBBFKNRK-UHFFFAOYSA-N 2-[(3,5-dichloropyridine-4-carbonyl)amino]-4-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy]butanoic acid Chemical compound ClC=1C=NC=C(C=1C(=O)NC(C(=O)O)CCOCCCCC1=NC=2NCCCC=2C=C1)Cl JNVPABCBBFKNRK-UHFFFAOYSA-N 0.000 claims 1
- LBQLMZKHUKBZCW-UHFFFAOYSA-N 2-[(3,6-dimethylpyridine-2-carbonyl)amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound CC=1C(=NC(=CC=1)C)C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1 LBQLMZKHUKBZCW-UHFFFAOYSA-N 0.000 claims 1
- QSXIDMFPMPCZTD-UHFFFAOYSA-N 2-[(3-chloro-5-fluoropyridine-4-carbonyl)amino]-4-[2-hydroxy-4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy]butanoic acid Chemical compound ClC=1C=NC=C(C=1C(=O)NC(C(=O)O)CCOCC(CCC1=NC=2NCCCC=2C=C1)O)F QSXIDMFPMPCZTD-UHFFFAOYSA-N 0.000 claims 1
- CLXOUWREWNHRAF-UHFFFAOYSA-N 2-[(3-chloro-5-fluoropyridine-4-carbonyl)amino]-4-[2-methyl-4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy]butanoic acid Chemical compound ClC=1C=NC=C(C=1C(=O)NC(C(=O)O)CCOCC(CCC1=NC=2NCCCC=2C=C1)C)F CLXOUWREWNHRAF-UHFFFAOYSA-N 0.000 claims 1
- XONXGUNEGARHQV-UHFFFAOYSA-N 2-[(3-chloro-5-fluoropyridine-4-carbonyl)amino]-4-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy]butanoic acid Chemical compound ClC=1C=NC=C(C=1C(=O)NC(C(=O)O)CCOCCCCC1=NC=2NCCCC=2C=C1)F XONXGUNEGARHQV-UHFFFAOYSA-N 0.000 claims 1
- YOUKWNQRORFDIC-UHFFFAOYSA-N 2-[(3-chloro-5-methoxypyridine-4-carbonyl)amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound ClC=1C=NC=C(C=1C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1)OC YOUKWNQRORFDIC-UHFFFAOYSA-N 0.000 claims 1
- MEAZBQPUFLWFME-UHFFFAOYSA-N 2-[(3-chloro-5-methylpyridine-4-carbonyl)amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound ClC=1C=NC=C(C=1C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1)C MEAZBQPUFLWFME-UHFFFAOYSA-N 0.000 claims 1
- ZORNTFCVYPXCJZ-UHFFFAOYSA-N 2-[(3-chloro-5-methylpyridine-4-carbonyl)amino]-4-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy]butanoic acid Chemical compound ClC=1C=NC=C(C=1C(=O)NC(C(=O)O)CCOCCCCC1=NC=2NCCCC=2C=C1)C ZORNTFCVYPXCJZ-UHFFFAOYSA-N 0.000 claims 1
- OFXVLIWLEVWDIY-UHFFFAOYSA-N 2-[(4,4-difluoro-3,3-dimethylbutanoyl)amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound FC(C(CC(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C)F OFXVLIWLEVWDIY-UHFFFAOYSA-N 0.000 claims 1
- QZCURXWQZJSMBB-UHFFFAOYSA-N 2-[(4-chloro-2-methylpyrazole-3-carbonyl)amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound ClC1=C(N(N=C1)C)C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1 QZCURXWQZJSMBB-UHFFFAOYSA-N 0.000 claims 1
- UBFUFLJDCPKNSR-UHFFFAOYSA-N 2-[(6-methoxy-2,4-dimethylpyridine-3-carbonyl)amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound COC1=CC(=C(C(=N1)C)C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1)C UBFUFLJDCPKNSR-UHFFFAOYSA-N 0.000 claims 1
- CXPMGHJWQVHHDL-UHFFFAOYSA-N 2-[[1-(2-phenylethyl)cyclopropanecarbonyl]amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound C1(=CC=CC=C1)CCC1(CC1)C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1 CXPMGHJWQVHHDL-UHFFFAOYSA-N 0.000 claims 1
- IZQDHESAARVSFL-UHFFFAOYSA-N 2-[[1-(4-propan-2-ylphenyl)cyclopentanecarbonyl]amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound C(C)(C)C1=CC=C(C=C1)C1(CCCC1)C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1 IZQDHESAARVSFL-UHFFFAOYSA-N 0.000 claims 1
- ZPUWZEMTYNVIHD-UHFFFAOYSA-N 2-[[1-(benzenesulfonyl)cyclopropanecarbonyl]amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound C1(=CC=CC=C1)S(=O)(=O)C1(CC1)C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1 ZPUWZEMTYNVIHD-UHFFFAOYSA-N 0.000 claims 1
- XUGCNROOVFMBEQ-UHFFFAOYSA-N 2-[[3-(difluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine-6-carbonyl]amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound FC(C1=NN=C2N1CC(CC2)C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1)F XUGCNROOVFMBEQ-UHFFFAOYSA-N 0.000 claims 1
- CZPHVWOMNQNSJT-UHFFFAOYSA-N 2-[[5-chloro-3-fluoro-2-[(4-methylpiperazin-1-yl)methyl]pyridine-4-carbonyl]amino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound ClC=1C(=C(C(=NC=1)CN1CCN(CC1)C)F)C(=O)NC(C(=O)O)CCOC1CC(C1)CCC1=NC=2NCCCC=2C=C1 CZPHVWOMNQNSJT-UHFFFAOYSA-N 0.000 claims 1
- CLZXTIJSAYKCAB-UHFFFAOYSA-N 3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxybutanoic acid Chemical compound C(C)(C)(C)OC(=O)NC(C(=O)O)C(COC1CC(C1)CCC1=NC=2NCCCC=2C=C1)C CLZXTIJSAYKCAB-UHFFFAOYSA-N 0.000 claims 1
- JYRGWUWUZOHHFE-UHFFFAOYSA-N 4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxy-2-[(4,4,4-trifluoro-3,3-dimethylbutanoyl)amino]butanoic acid Chemical compound N1=C(C=CC=2CCCNC1=2)CCC1CC(C1)OCCC(C(=O)O)NC(CC(C(F)(F)F)(C)C)=O JYRGWUWUZOHHFE-UHFFFAOYSA-N 0.000 claims 1
- TYIXUOALCOZMFC-UHFFFAOYSA-N 4-[3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]cyclobutyl]oxy-2-[2-[3-(trifluoromethyl)phenyl]butanoylamino]butanoic acid Chemical compound N1=C(C=CC=2CCCNC1=2)CCC1CC(C1)OCCC(C(=O)O)NC(C(CC)C1=CC(=CC=C1)C(F)(F)F)=O TYIXUOALCOZMFC-UHFFFAOYSA-N 0.000 claims 1
- GXTWFQYNXNARPJ-GQOXECLESA-N C(C(C)C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C(C)C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 GXTWFQYNXNARPJ-GQOXECLESA-N 0.000 claims 1
- VYAARYHYWCFSAN-IOYBJCICSA-N C(C)(=O)N1CC(C1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(=O)N1CC(C1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 VYAARYHYWCFSAN-IOYBJCICSA-N 0.000 claims 1
- POBPHCHGCFBIKE-UDJZJCJKSA-N C(C)(=O)N1CCC(CC1)(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)C(F)(F)F Chemical compound C(C)(=O)N1CCC(CC1)(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)C(F)(F)F POBPHCHGCFBIKE-UDJZJCJKSA-N 0.000 claims 1
- UHDLWURXFYPWIQ-JITJBCMDSA-N C(C)(C)(C)C1=CC(=NC=N1)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)(C)C1=CC(=NC=N1)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 UHDLWURXFYPWIQ-JITJBCMDSA-N 0.000 claims 1
- UIHCENIFBSVKGV-SUIMDOTNSA-N C(C)(C)(C)C1=CC=C(C=C1)C1(CCC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)(C)C1=CC=C(C=C1)C1(CCC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 UIHCENIFBSVKGV-SUIMDOTNSA-N 0.000 claims 1
- BARUQCVHHKWWOK-JITJBCMDSA-N C(C)(C)(C)C1=NC(=NC=C1)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)(C)C1=NC(=NC=C1)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 BARUQCVHHKWWOK-JITJBCMDSA-N 0.000 claims 1
- WYWRUFCRPPVSHF-OFHXQBPLSA-N C(C)(C)(C)OC(=O)N1CC(C1)(C1=CC(=CC=C1)Cl)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)(C)OC(=O)N1CC(C1)(C1=CC(=CC=C1)Cl)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 WYWRUFCRPPVSHF-OFHXQBPLSA-N 0.000 claims 1
- DXCSJGCPMCKFRB-IFVGDZTKSA-N C(C)(C)(C)OC(=O)N1CC(C1)(C1=CC=C(C=C1)C(C)C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)(C)OC(=O)N1CC(C1)(C1=CC=C(C=C1)C(C)C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 DXCSJGCPMCKFRB-IFVGDZTKSA-N 0.000 claims 1
- IDILDPDDIFRSTD-IVXJCAOYSA-N C(C)(C)(C)OC(=O)N1CC(C1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)(C)OC(=O)N1CC(C1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 IDILDPDDIFRSTD-IVXJCAOYSA-N 0.000 claims 1
- XVUTVZNWVYKENY-FTVZZTLYSA-N C(C)(C)(C)OC(=O)N1CC(CC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)(C)OC(=O)N1CC(CC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 XVUTVZNWVYKENY-FTVZZTLYSA-N 0.000 claims 1
- GQNWKHDCWYQXTN-TVNWEXPRSA-N C(C)(C)(C)OC(=O)N1CCC(CC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)(C)OC(=O)N1CCC(CC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 GQNWKHDCWYQXTN-TVNWEXPRSA-N 0.000 claims 1
- SMBAYWITXKRDBX-PPSBMQLTSA-N C(C)(C)(C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)(C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 SMBAYWITXKRDBX-PPSBMQLTSA-N 0.000 claims 1
- MNDXAZJWZIDPQQ-KRWDZBQOSA-N C(C)(C)(C)OC(=O)ON([C@@H](CCO)C(=O)O)CCCCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)(C)OC(=O)ON([C@@H](CCO)C(=O)O)CCCCC1=NC=2NCCCC=2C=C1 MNDXAZJWZIDPQQ-KRWDZBQOSA-N 0.000 claims 1
- QBPDYLDQLRALMX-FNEQHPHYSA-N C(C)C(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(CC)C1=CC=CC=C1 Chemical compound C(C)C(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(CC)C1=CC=CC=C1 QBPDYLDQLRALMX-FNEQHPHYSA-N 0.000 claims 1
- RDGRYSJHGSRVCD-RTJZXMOCSA-N C(C)C(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)CC(F)(F)F Chemical compound C(C)C(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)CC(F)(F)F RDGRYSJHGSRVCD-RTJZXMOCSA-N 0.000 claims 1
- AMBUMIMMNKTIOX-RTJZXMOCSA-N C(C)C(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)CC(F)F Chemical compound C(C)C(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)CC(F)F AMBUMIMMNKTIOX-RTJZXMOCSA-N 0.000 claims 1
- SLBFFHDHUBQANA-GHXXTNBWSA-N C1(=CC=CC=C1)C#CC1C(CCCC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C1(=CC=CC=C1)C#CC1C(CCCC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 SLBFFHDHUBQANA-GHXXTNBWSA-N 0.000 claims 1
- OJCLQCHWOMDLBC-TVNWEXPRSA-N C1(=CC=CC=C1)C1(CC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C1(=CC=CC=C1)C1(CC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 OJCLQCHWOMDLBC-TVNWEXPRSA-N 0.000 claims 1
- LCPBVRSQFVUNFL-VZTJNBFISA-N C1(=CC=CC=C1)C1(CCC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C1(=CC=CC=C1)C1(CCC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 LCPBVRSQFVUNFL-VZTJNBFISA-N 0.000 claims 1
- OHKKXIWLUQGAHT-SNYWLETKSA-N C1(=CC=CC=C1)C1C(CC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C1(=CC=CC=C1)C1C(CC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 OHKKXIWLUQGAHT-SNYWLETKSA-N 0.000 claims 1
- UWEPIOVHLSILOP-OFENFNCUSA-N C1(=CC=CC=C1)C1CC(C1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C1(=CC=CC=C1)C1CC(C1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 UWEPIOVHLSILOP-OFENFNCUSA-N 0.000 claims 1
- ZQNPKOMNCWTCSI-ZZXNFCGKSA-N C1(=CC=CC=C1)C1CCC(CC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C1(=CC=CC=C1)C1CCC(CC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 ZQNPKOMNCWTCSI-ZZXNFCGKSA-N 0.000 claims 1
- MHRLNIRFYBTFOW-KABUSDLNSA-N C1(=CC=CC=C1)S(=O)(=O)N1C(CCCC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C1(=CC=CC=C1)S(=O)(=O)N1C(CCCC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 MHRLNIRFYBTFOW-KABUSDLNSA-N 0.000 claims 1
- OKZTWQDCTLHWLJ-WISNAQHKSA-N C1(=NC=CC2=CC=CC=C12)C1(CC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C1(=NC=CC2=CC=CC=C12)C1(CC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 OKZTWQDCTLHWLJ-WISNAQHKSA-N 0.000 claims 1
- WLKLCAFBUHSOLW-RPRDLGQTSA-N C1(CCC2=CC=CC=C12)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C1(CCC2=CC=CC=C12)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 WLKLCAFBUHSOLW-RPRDLGQTSA-N 0.000 claims 1
- FZFLEGZAKAYNKU-TVNWEXPRSA-N C1(CCCCC1)C(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C Chemical compound C1(CCCCC1)C(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C FZFLEGZAKAYNKU-TVNWEXPRSA-N 0.000 claims 1
- VOZVREDUXSLKJJ-QVHXHXEWSA-N C1(CCCCC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C1(CCCCC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 VOZVREDUXSLKJJ-QVHXHXEWSA-N 0.000 claims 1
- UVEVOEWCTAJQIW-VHNLKAGOSA-N C1C(CC2=CC=CC=C12)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C1C(CC2=CC=CC=C12)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 UVEVOEWCTAJQIW-VHNLKAGOSA-N 0.000 claims 1
- VPIBBCIATCRMMJ-CKRJSAQMSA-N CC(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C=1C=NC=CC=1 Chemical compound CC(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C=1C=NC=CC=1 VPIBBCIATCRMMJ-CKRJSAQMSA-N 0.000 claims 1
- XQNFATHDIXSFHR-GQOXECLESA-N CC(CC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C Chemical compound CC(CC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C XQNFATHDIXSFHR-GQOXECLESA-N 0.000 claims 1
- WLDIMVJRSOKMOU-PPSBMQLTSA-N CC1(CC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CC1(CC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 WLDIMVJRSOKMOU-PPSBMQLTSA-N 0.000 claims 1
- RVGBNDIUVIHOSC-FMKHTLPYSA-N CC1(CC2=CC=CC=C2CC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CC1(CC2=CC=CC=C2CC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 RVGBNDIUVIHOSC-FMKHTLPYSA-N 0.000 claims 1
- CSVCDQIWUAFCEE-PPSBMQLTSA-N CC1(CNC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CC1(CNC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 CSVCDQIWUAFCEE-PPSBMQLTSA-N 0.000 claims 1
- QZOXUGZFCFRNOG-DLUKIOLESA-N CC1=CC=C2C(=NC=NC2=C1)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CC1=CC=C2C(=NC=NC2=C1)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 QZOXUGZFCFRNOG-DLUKIOLESA-N 0.000 claims 1
- IZJQTCLKUCAEFC-FNEQHPHYSA-N CC1=CC=C2CCN(C2=C1)C(=O)C1(CC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CC1=CC=C2CCN(C2=C1)C(=O)C1(CC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 IZJQTCLKUCAEFC-FNEQHPHYSA-N 0.000 claims 1
- DNACQJHSVPUEQW-TXSRUQCCSA-N CC1N(C(CC1)C)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CC1N(C(CC1)C)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 DNACQJHSVPUEQW-TXSRUQCCSA-N 0.000 claims 1
- WBHQLHVBEMJXGC-XRUJOLSKSA-N CC1N(C(CCC1)C)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CC1N(C(CCC1)C)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 WBHQLHVBEMJXGC-XRUJOLSKSA-N 0.000 claims 1
- UKTAHNIUWONWLR-TXSRUQCCSA-N CC1N(C(COC1)C)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CC1N(C(COC1)C)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 UKTAHNIUWONWLR-TXSRUQCCSA-N 0.000 claims 1
- ZWPRMFJVYGKWDT-UHYCVJNDSA-N CC1N(C(COC1)C)C(=O)ON([C@@H](CCO)C(=O)O)CCCCC1=NC=2NCCCC=2C=C1 Chemical compound CC1N(C(COC1)C)C(=O)ON([C@@H](CCO)C(=O)O)CCCCC1=NC=2NCCCC=2C=C1 ZWPRMFJVYGKWDT-UHYCVJNDSA-N 0.000 claims 1
- DRDABHKCNJEODO-DFTBRHRKSA-N CC=1N(C(C=C(C=1C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)C)=O)C1=CC=CC=C1 Chemical compound CC=1N(C(C=C(C=1C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)C)=O)C1=CC=CC=C1 DRDABHKCNJEODO-DFTBRHRKSA-N 0.000 claims 1
- RSASWOQVVVQPOG-JITJBCMDSA-N CC=1NC(C=C(C=1C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)C)=O Chemical compound CC=1NC(C=C(C=1C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)C)=O RSASWOQVVVQPOG-JITJBCMDSA-N 0.000 claims 1
- JMIGLWUNTMGMCN-MLFGXNJISA-N CN1C=CC2=C1N=CC=C2C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CN1C=CC2=C1N=CC=C2C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 JMIGLWUNTMGMCN-MLFGXNJISA-N 0.000 claims 1
- MGMJYAQAWGTHPC-PYPWZVKOSA-N CN1N=CC(=C1)C1(OCCC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CN1N=CC(=C1)C1(OCCC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 MGMJYAQAWGTHPC-PYPWZVKOSA-N 0.000 claims 1
- GELIGEIZZSEFKG-KGGRFHARSA-N CN1N=CC=2C(=CC=CC1=2)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CN1N=CC=2C(=CC=CC1=2)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 GELIGEIZZSEFKG-KGGRFHARSA-N 0.000 claims 1
- WHISAKVEOBGUAL-GQOXECLESA-N CS(=O)(=O)CCCC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CS(=O)(=O)CCCC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 WHISAKVEOBGUAL-GQOXECLESA-N 0.000 claims 1
- JPDIZYLISXTLOT-IIXJVVKQSA-N FC1(C(C1)(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)C=1C=C(C=CC=1)C)F Chemical compound FC1(C(C1)(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)C=1C=C(C=CC=1)C)F JPDIZYLISXTLOT-IIXJVVKQSA-N 0.000 claims 1
- LJEJTLIARYAJLR-NZBFNNPHSA-N FC1=C2C(=NC=NC2=CC=C1)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound FC1=C2C(=NC=NC2=CC=C1)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 LJEJTLIARYAJLR-NZBFNNPHSA-N 0.000 claims 1
- GDFKDOSBEGSKIM-WQMGSUCASA-N FC1=CC=C(C=C1)C(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C Chemical compound FC1=CC=C(C=C1)C(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C GDFKDOSBEGSKIM-WQMGSUCASA-N 0.000 claims 1
- NVAMWQKQQAKAPM-JCJCGPQSSA-N FC1=CC=C2C(=NC=NC2=C1)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound FC1=CC=C2C(=NC=NC2=C1)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 NVAMWQKQQAKAPM-JCJCGPQSSA-N 0.000 claims 1
- NNDQOPUAFXNWTH-NZBFNNPHSA-N FC=1C=CC=C2C(=NC=NC=12)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound FC=1C=CC=C2C(=NC=NC=12)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 NNDQOPUAFXNWTH-NZBFNNPHSA-N 0.000 claims 1
- UUIQMZJEGPQKFD-UHFFFAOYSA-N Methyl butyrate Chemical compound CCCC(=O)OC UUIQMZJEGPQKFD-UHFFFAOYSA-N 0.000 claims 1
- WXXQWIROHMGNTF-MLFGXNJISA-N N1=CN=C(C2=CC=CC=C12)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound N1=CN=C(C2=CC=CC=C12)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 WXXQWIROHMGNTF-MLFGXNJISA-N 0.000 claims 1
- ARMCZHYGPCXDNO-NZBFNNPHSA-N N1C=CC2=NC=CC(=C21)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound N1C=CC2=NC=CC(=C21)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 ARMCZHYGPCXDNO-NZBFNNPHSA-N 0.000 claims 1
- VBZPROHBRBAQHR-DJKWIZAZSA-N N1CC(CC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound N1CC(CC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 VBZPROHBRBAQHR-DJKWIZAZSA-N 0.000 claims 1
- XXXPKNDJLXPIEL-PPSBMQLTSA-N OCC(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C Chemical compound OCC(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)(C)C XXXPKNDJLXPIEL-PPSBMQLTSA-N 0.000 claims 1
- HCVJTCWUULLGEU-OIYWLGGTSA-N OCC(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)C1=CC=CC=C1 Chemical compound OCC(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)C1=CC=CC=C1 HCVJTCWUULLGEU-OIYWLGGTSA-N 0.000 claims 1
- SNVCQQCZLNQNCH-MOQPWLNLSA-N OCC[C@@H](C(O)=O)NC1CC(CCC2=NC(NCCC3)=C3C=C2)C1 Chemical compound OCC[C@@H](C(O)=O)NC1CC(CCC2=NC(NCCC3)=C3C=C2)C1 SNVCQQCZLNQNCH-MOQPWLNLSA-N 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 230000008520 organization Effects 0.000 claims 1
- 201000004071 non-specific interstitial pneumonia Diseases 0.000 abstract description 11
- 239000003112 inhibitor Substances 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 description 204
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 143
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 124
- 125000006413 ring segment Chemical group 0.000 description 76
- 125000004432 carbon atom Chemical group C* 0.000 description 72
- 238000006243 chemical reaction Methods 0.000 description 54
- 235000019439 ethyl acetate Nutrition 0.000 description 52
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 50
- 239000000243 solution Substances 0.000 description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 35
- 229940024606 amino acid Drugs 0.000 description 31
- 235000001014 amino acid Nutrition 0.000 description 31
- 239000002585 base Substances 0.000 description 31
- 239000010410 layer Substances 0.000 description 31
- 239000012071 phase Substances 0.000 description 31
- 239000011541 reaction mixture Substances 0.000 description 27
- 230000002829 reductive effect Effects 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 239000000460 chlorine Substances 0.000 description 26
- 229910052757 nitrogen Inorganic materials 0.000 description 26
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 24
- 229920006395 saturated elastomer Polymers 0.000 description 22
- KYARBIJYVGJZLB-UHFFFAOYSA-N 7-amino-4-hydroxy-2-naphthalenesulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=CC2=CC(N)=CC=C21 KYARBIJYVGJZLB-UHFFFAOYSA-N 0.000 description 21
- 229910052760 oxygen Inorganic materials 0.000 description 21
- 238000010898 silica gel chromatography Methods 0.000 description 21
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- 125000005842 heteroatom Chemical group 0.000 description 20
- 239000012535 impurity Substances 0.000 description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- 239000000725 suspension Substances 0.000 description 20
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 19
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- 239000001301 oxygen Substances 0.000 description 19
- 239000003208 petroleum Substances 0.000 description 19
- 230000008569 process Effects 0.000 description 19
- 238000000746 purification Methods 0.000 description 19
- 229940079593 drug Drugs 0.000 description 18
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 18
- 239000012044 organic layer Substances 0.000 description 18
- 238000004440 column chromatography Methods 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 125000001309 chloro group Chemical group Cl* 0.000 description 16
- 239000012043 crude product Substances 0.000 description 16
- 239000000284 extract Substances 0.000 description 16
- 229910052731 fluorine Inorganic materials 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- 239000011734 sodium Substances 0.000 description 15
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 14
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
- QDMZCBABQCORRW-BYPYZUCNSA-N methyl (2s)-2-amino-4-hydroxybutanoate Chemical compound COC(=O)[C@@H](N)CCO QDMZCBABQCORRW-BYPYZUCNSA-N 0.000 description 14
- 238000006467 substitution reaction Methods 0.000 description 14
- 229910052717 sulfur Chemical group 0.000 description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 230000008878 coupling Effects 0.000 description 13
- 238000010168 coupling process Methods 0.000 description 13
- 238000005859 coupling reaction Methods 0.000 description 13
- 239000011593 sulfur Chemical group 0.000 description 13
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 12
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 238000004808 supercritical fluid chromatography Methods 0.000 description 12
- 239000003921 oil Substances 0.000 description 11
- 125000001424 substituent group Chemical group 0.000 description 11
- 238000004809 thin layer chromatography Methods 0.000 description 11
- 239000012267 brine Substances 0.000 description 10
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- 229910004298 SiO 2 Inorganic materials 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 125000002993 cycloalkylene group Chemical group 0.000 description 9
- 230000008570 general process Effects 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- ATUUSOSLBXVJKL-UHFFFAOYSA-N 3-ethylpentanoic acid Chemical compound CCC(CC)CC(O)=O ATUUSOSLBXVJKL-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 125000004450 alkenylene group Chemical group 0.000 description 8
- 150000001350 alkyl halides Chemical class 0.000 description 8
- 125000004419 alkynylene group Chemical group 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000011737 fluorine Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 8
- 229910052740 iodine Inorganic materials 0.000 description 8
- 125000006574 non-aromatic ring group Chemical group 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 229910052700 potassium Inorganic materials 0.000 description 8
- TUHPRPIQWXZJQE-UHFFFAOYSA-N 3-(1,3-thiazol-5-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C=2SC=NC=2)=C1 TUHPRPIQWXZJQE-UHFFFAOYSA-N 0.000 description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 239000007937 lozenge Substances 0.000 description 7
- 238000007248 oxidative elimination reaction Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000002953 preparative HPLC Methods 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 6
- WJYAYXKXZNITAZ-UHFFFAOYSA-N 2-chloro-3-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC(F)=C1Cl WJYAYXKXZNITAZ-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 108010017642 Integrin alpha2beta1 Proteins 0.000 description 6
- 108010030465 Integrin alpha6beta1 Proteins 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 239000003638 chemical reducing agent Substances 0.000 description 6
- 229940127271 compound 49 Drugs 0.000 description 6
- 125000000392 cycloalkenyl group Chemical group 0.000 description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- UBHZUDXTHNMNLD-UHFFFAOYSA-N dimethylsilane Chemical compound C[SiH2]C UBHZUDXTHNMNLD-UHFFFAOYSA-N 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 230000026045 iodination Effects 0.000 description 6
- 238000006192 iodination reaction Methods 0.000 description 6
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- QKAIIJHXZDNKMY-BYPYZUCNSA-N (2s)-4-hydroxy-2-(methylamino)butanoic acid Chemical compound CN[C@H](C(O)=O)CCO QKAIIJHXZDNKMY-BYPYZUCNSA-N 0.000 description 5
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 5
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 5
- QBXVXKRWOVBUDB-GRKNLSHJSA-N ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C Chemical compound ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C QBXVXKRWOVBUDB-GRKNLSHJSA-N 0.000 description 5
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 206010061989 glomerulosclerosis Diseases 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000002480 mineral oil Substances 0.000 description 5
- 235000010446 mineral oil Nutrition 0.000 description 5
- 230000000750 progressive effect Effects 0.000 description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 5
- 238000006884 silylation reaction Methods 0.000 description 5
- 125000003003 spiro group Chemical group 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 4
- IWYDHOAUDWTVEP-SSDOTTSWSA-N (R)-mandelic acid Chemical compound OC(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-N 0.000 description 4
- JACRWUWPXAESPB-QMMMGPOBSA-N (R)-tropic acid Chemical compound OC[C@H](C(O)=O)C1=CC=CC=C1 JACRWUWPXAESPB-QMMMGPOBSA-N 0.000 description 4
- IWYDHOAUDWTVEP-ZETCQYMHSA-N (S)-mandelic acid Chemical compound OC(=O)[C@@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-ZETCQYMHSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- JBQMFBWTKWOSQX-UHFFFAOYSA-N 2,3-dihydro-1h-indene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)CCC2=C1 JBQMFBWTKWOSQX-UHFFFAOYSA-N 0.000 description 4
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 4
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- CYSWUSAYJNCAKA-FYJFLYSWSA-N ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O Chemical compound ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O CYSWUSAYJNCAKA-FYJFLYSWSA-N 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241000872931 Myoporum sandwicense Species 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 210000000941 bile Anatomy 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 229940126545 compound 53 Drugs 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 4
- QAPTWHXHEYAIKG-RCOXNQKVSA-N n-[(1r,2s,5r)-5-(tert-butylamino)-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 QAPTWHXHEYAIKG-RCOXNQKVSA-N 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- 238000000844 transformation Methods 0.000 description 4
- 229940005605 valeric acid Drugs 0.000 description 4
- HDKWKDXEBFQOHD-NXEZZACHSA-N (1R,2R)-2-(3,5-dimethylpyrazol-1-yl)cyclopentan-1-ol Chemical compound Cc1cc(C)n(n1)[C@@H]1CCC[C@H]1O HDKWKDXEBFQOHD-NXEZZACHSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- QRDAPCMJAOQZSU-KQQUZDAGSA-N (e)-3-[4-[(e)-3-(3-fluorophenyl)-3-oxoprop-1-enyl]-1-methylpyrrol-2-yl]-n-hydroxyprop-2-enamide Chemical compound C1=C(\C=C\C(=O)NO)N(C)C=C1\C=C\C(=O)C1=CC=CC(F)=C1 QRDAPCMJAOQZSU-KQQUZDAGSA-N 0.000 description 3
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 3
- NXMFJCRMSDRXLD-UHFFFAOYSA-N 2-aminopyridine-3-carbaldehyde Chemical compound NC1=NC=CC=C1C=O NXMFJCRMSDRXLD-UHFFFAOYSA-N 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 3
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 3
- REDUQXCPUSNJOL-UHFFFAOYSA-N C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O Chemical compound C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O REDUQXCPUSNJOL-UHFFFAOYSA-N 0.000 description 3
- UKAUYVFTDYCKQA-GSVOUGTGSA-N D-homoserine Chemical compound OC(=O)[C@H](N)CCO UKAUYVFTDYCKQA-GSVOUGTGSA-N 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 229920002148 Gellan gum Polymers 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108010072255 Integrin alpha3beta1 Proteins 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- 229930182821 L-proline Natural products 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 3
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
- 239000000605 aspartame Substances 0.000 description 3
- 235000010357 aspartame Nutrition 0.000 description 3
- 229960003438 aspartame Drugs 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- KSCRVOKQPYZBHZ-IXPOFIJOSA-N benzyl n-[(2s)-1-[[(2s)-1-[[(2s)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@H]1C(NCC1)=O)C(=O)C=1SC2=CC=CC=C2N=1)C(C)C)C(=O)OCC1=CC=CC=C1 KSCRVOKQPYZBHZ-IXPOFIJOSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 235000010492 gellan gum Nutrition 0.000 description 3
- 239000000216 gellan gum Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 108010059115 integrin alpha11beta1 Proteins 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 229960002429 proline Drugs 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 230000036573 scar formation Effects 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- SIPPACGSOBTDRS-UHFFFAOYSA-N tert-butyl 3-hydroxy-3-(4-propan-2-ylphenyl)azetidine-1-carboxylate Chemical compound C1=CC(C(C)C)=CC=C1C1(O)CN(C(=O)OC(C)(C)C)C1 SIPPACGSOBTDRS-UHFFFAOYSA-N 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 229940126135 αvβ6 integrin inhibitor Drugs 0.000 description 3
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 2
- VPMIAOSOTOODMY-KJAPKAAFSA-N (4r)-6-[(e)-2-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1/C=C/C=1C(C(C)C)=NC(C(C)(C)C)=CC=1C1=CC=C(F)C=C1 VPMIAOSOTOODMY-KJAPKAAFSA-N 0.000 description 2
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 2
- VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 2
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 description 2
- JACRWUWPXAESPB-MRVPVSSYSA-N (S)-tropic acid Chemical compound OC[C@@H](C(O)=O)C1=CC=CC=C1 JACRWUWPXAESPB-MRVPVSSYSA-N 0.000 description 2
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- JHZRNLRTNIDFKG-UHFFFAOYSA-N 1-phenylcyclobutane-1-carboxylic acid Chemical compound C=1C=CC=CC=1C1(C(=O)O)CCC1 JHZRNLRTNIDFKG-UHFFFAOYSA-N 0.000 description 2
- IWWCCNVRNHTGLV-UHFFFAOYSA-N 1-phenylcyclopropane-1-carboxylic acid Chemical compound C=1C=CC=CC=1C1(C(=O)O)CC1 IWWCCNVRNHTGLV-UHFFFAOYSA-N 0.000 description 2
- BQHWATVEWGHHHF-UHFFFAOYSA-N 2,2-dimethyl-3-phenylpropanoic acid Chemical compound OC(=O)C(C)(C)CC1=CC=CC=C1 BQHWATVEWGHHHF-UHFFFAOYSA-N 0.000 description 2
- XUDCMQBOWOLYCF-UHFFFAOYSA-N 2,3-dihydro-1h-indene-2-carboxylic acid Chemical compound C1=CC=C2CC(C(=O)O)CC2=C1 XUDCMQBOWOLYCF-UHFFFAOYSA-N 0.000 description 2
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 2
- VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 description 2
- DTLIEBPGBUWODB-UHFFFAOYSA-N 2-(2-ethylbutanoylamino)-5-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propoxy]pentanoic acid Chemical compound C(C)C(C(=O)NC(C(=O)O)CCCOCCCC1=NC=2NCCCC=2C=C1)CC DTLIEBPGBUWODB-UHFFFAOYSA-N 0.000 description 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- IGPDGDPRWAYQSD-UHFFFAOYSA-N 2-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy]acetaldehyde Chemical compound N1=C(C=CC=2CCCNC1=2)CCCCOCC=O IGPDGDPRWAYQSD-UHFFFAOYSA-N 0.000 description 2
- RTXDKVFNAOMDFV-UHFFFAOYSA-N 2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetic acid Chemical compound COP(=O)(OC)C(C(O)=O)NC(=O)OCC1=CC=CC=C1 RTXDKVFNAOMDFV-UHFFFAOYSA-N 0.000 description 2
- YYEROYLAYAVZNW-UHFFFAOYSA-N 2-methyl-2-phenylpropanoic acid Chemical compound OC(=O)C(C)(C)C1=CC=CC=C1 YYEROYLAYAVZNW-UHFFFAOYSA-N 0.000 description 2
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 2
- XFOWYEKVIRMOBI-UHFFFAOYSA-N 3,3-dimethylbutanenitrile Chemical compound CC(C)(C)CC#N XFOWYEKVIRMOBI-UHFFFAOYSA-N 0.000 description 2
- FPENCTDAQQQKNY-UHFFFAOYSA-N 3,4-difluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C(F)=C1 FPENCTDAQQQKNY-UHFFFAOYSA-N 0.000 description 2
- ADEBTUFPSZKNOA-UHFFFAOYSA-N 3-(1-methylpyrazol-4-yl)benzoic acid Chemical compound C1=NN(C)C=C1C1=CC=CC(C(O)=O)=C1 ADEBTUFPSZKNOA-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
- NSGKIIGVPBTOBF-UHFFFAOYSA-N 3-fluoro-5-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC(F)=CC(C(F)(F)F)=C1 NSGKIIGVPBTOBF-UHFFFAOYSA-N 0.000 description 2
- RDFQSFOGKVZWKF-UHFFFAOYSA-N 3-hydroxy-2,2-dimethylpropanoic acid Chemical compound OCC(C)(C)C(O)=O RDFQSFOGKVZWKF-UHFFFAOYSA-N 0.000 description 2
- FLFLSQGRBROAPA-UHFFFAOYSA-N 3-methoxy-2,2-dimethylpropanoic acid Chemical compound COCC(C)(C)C(O)=O FLFLSQGRBROAPA-UHFFFAOYSA-N 0.000 description 2
- PMPZEEUNGQSAIQ-UHFFFAOYSA-N 3-methyloxetane-3-carboxylic acid Chemical compound OC(=O)C1(C)COC1 PMPZEEUNGQSAIQ-UHFFFAOYSA-N 0.000 description 2
- MTLNUCHJTJRGOZ-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butan-1-ol Chemical compound C1CCNC2=NC(CCCCO)=CC=C21 MTLNUCHJTJRGOZ-UHFFFAOYSA-N 0.000 description 2
- RNQDBLUYYSHGRP-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butanoic acid;hydrochloride Chemical compound Cl.C1CCNC2=NC(CCCC(=O)O)=CC=C21 RNQDBLUYYSHGRP-UHFFFAOYSA-N 0.000 description 2
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 2
- BBYDXOIZLAWGSL-UHFFFAOYSA-N 4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1 BBYDXOIZLAWGSL-UHFFFAOYSA-N 0.000 description 2
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 2
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 2
- 101150065749 Churc1 gene Proteins 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000238367 Mya arenaria Species 0.000 description 2
- SUKXKLNDBLNTSW-UHFFFAOYSA-N N-(4-hydroxycyclohexyl)-6-phenylhexanamide Chemical compound OC1CCC(CC1)NC(CCCCCC1=CC=CC=C1)=O SUKXKLNDBLNTSW-UHFFFAOYSA-N 0.000 description 2
- 229910017906 NH3H2O Inorganic materials 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100038239 Protein Churchill Human genes 0.000 description 2
- JACRWUWPXAESPB-UHFFFAOYSA-N S-tropic acid Natural products OCC(C(O)=O)C1=CC=CC=C1 JACRWUWPXAESPB-UHFFFAOYSA-N 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- OJFKUJDRGJSAQB-UHFFFAOYSA-N TAK-632 Chemical compound C1=C(NC(=O)CC=2C=C(C=CC=2)C(F)(F)F)C(F)=CC=C1OC(C(=C1S2)C#N)=CC=C1N=C2NC(=O)C1CC1 OJFKUJDRGJSAQB-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 210000004712 air sac Anatomy 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000012455 biphasic mixture Substances 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 208000003167 cholangitis Diseases 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 229940125878 compound 36 Drugs 0.000 description 2
- 229940126179 compound 72 Drugs 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical compound OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 2
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 239000003979 granulating agent Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 239000008241 heterogeneous mixture Substances 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000005414 inactive ingredient Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- OSUPUGFYHLNTLX-UHFFFAOYSA-N methyl 2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy]but-2-enoate Chemical compound C(C)(C)(C)OC(=O)NC(C(=O)OC)=CCOCCCCC1=NC=2NCCCC=2C=C1 OSUPUGFYHLNTLX-UHFFFAOYSA-N 0.000 description 2
- LJHAPRKTPAREGO-UHFFFAOYSA-N methyl 2-dimethoxyphosphoryl-2-[(2-methylpropan-2-yl)oxycarbonylamino]acetate Chemical compound COC(=O)C(P(=O)(OC)OC)NC(=O)OC(C)(C)C LJHAPRKTPAREGO-UHFFFAOYSA-N 0.000 description 2
- OJHUHKKURDTCEL-UHFFFAOYSA-N methyl 3-(1,3-thiazol-5-yl)benzoate Chemical compound COC(=O)C1=CC=CC(C=2SC=NC=2)=C1 OJHUHKKURDTCEL-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- IDSMDKUVIBSETN-UHFFFAOYSA-N n-methyl-n-(propan-2-ylideneamino)methanamine Chemical compound CN(C)N=C(C)C IDSMDKUVIBSETN-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 201000009925 nephrosclerosis Diseases 0.000 description 2
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 201000002793 renal fibrosis Diseases 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 150000003355 serines Chemical class 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 2
- 239000001476 sodium potassium tartrate Substances 0.000 description 2
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- KZXMKKSDVITCAY-UHFFFAOYSA-N tert-butyl 7-(4-hydroxybutyl)-3,4-dihydro-2H-1,8-naphthyridine-1-carboxylate Chemical compound OCCCCC1=CC=C2CCCN(C2=N1)C(=O)OC(C)(C)C KZXMKKSDVITCAY-UHFFFAOYSA-N 0.000 description 2
- UKKDZRGPGFGAJF-UHFFFAOYSA-N tert-butyl 7-(4-oxobutyl)-3,4-dihydro-2H-1,8-naphthyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCc2ccc(CCCC=O)nc12 UKKDZRGPGFGAJF-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 2
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000011277 treatment modality Methods 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- LQUPKVMEAATBSL-UHFFFAOYSA-L zinc;2,3,4-trichlorophenolate Chemical compound [Zn+2].[O-]C1=CC=C(Cl)C(Cl)=C1Cl.[O-]C1=CC=C(Cl)C(Cl)=C1Cl LQUPKVMEAATBSL-UHFFFAOYSA-L 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- GJEZBVHHZQAEDB-SYDPRGILSA-N (1s,5r)-6-oxabicyclo[3.1.0]hexane Chemical compound C1CC[C@H]2O[C@H]21 GJEZBVHHZQAEDB-SYDPRGILSA-N 0.000 description 1
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- ALTLCJHSJMGSLT-UHFFFAOYSA-N (3-methoxycarbonylphenyl)boronic acid Chemical compound COC(=O)C1=CC=CC(B(O)O)=C1 ALTLCJHSJMGSLT-UHFFFAOYSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 description 1
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 1
- DJMOXMNDXFFONV-UHFFFAOYSA-N 1,3-dimethyl-7-[2-(n-methylanilino)ethyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCN(C)C1=CC=CC=C1 DJMOXMNDXFFONV-UHFFFAOYSA-N 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N 1-Heptene Chemical group CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- TYQSPGDKGHTOLA-UHFFFAOYSA-N 1-methylindazole-4-carboxylic acid Chemical compound C1=CC=C2N(C)N=CC2=C1C(O)=O TYQSPGDKGHTOLA-UHFFFAOYSA-N 0.000 description 1
- FDPGPKFADPMZLJ-UHFFFAOYSA-N 1-methylpyrrolo[2,3-b]pyridine-4-carboxylic acid Chemical compound C1=CN=C2N(C)C=CC2=C1C(O)=O FDPGPKFADPMZLJ-UHFFFAOYSA-N 0.000 description 1
- QAEFMEIYIBNWLW-UHFFFAOYSA-N 1-methylpyrrolo[2,3-b]pyridine-5-carboxylic acid Chemical compound OC(=O)C1=CN=C2N(C)C=CC2=C1 QAEFMEIYIBNWLW-UHFFFAOYSA-N 0.000 description 1
- JUUBFHLPTCPVBO-UHFFFAOYSA-N 2,2-dimethylpropyl carbonochloridate Chemical compound CC(C)(C)COC(Cl)=O JUUBFHLPTCPVBO-UHFFFAOYSA-N 0.000 description 1
- QAOJBHRZQQDFHA-UHFFFAOYSA-N 2,3-dichlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1Cl QAOJBHRZQQDFHA-UHFFFAOYSA-N 0.000 description 1
- JLZVIWSFUPLSOR-UHFFFAOYSA-N 2,3-difluorobenzoic acid Chemical compound OC(=O)C1=CC=CC(F)=C1F JLZVIWSFUPLSOR-UHFFFAOYSA-N 0.000 description 1
- NJYBIFYEWYWYAN-UHFFFAOYSA-N 2,4-difluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1F NJYBIFYEWYWYAN-UHFFFAOYSA-N 0.000 description 1
- LBQMIAVIGLLBGW-UHFFFAOYSA-N 2,5-difluorobenzoic acid Chemical compound OC(=O)C1=CC(F)=CC=C1F LBQMIAVIGLLBGW-UHFFFAOYSA-N 0.000 description 1
- ONOTYLMNTZNAQZ-UHFFFAOYSA-N 2,6-difluorobenzoic acid Chemical compound OC(=O)C1=C(F)C=CC=C1F ONOTYLMNTZNAQZ-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- MIZKCMSSYVUZKD-UHFFFAOYSA-N 2-chloro-5-fluorobenzoic acid Chemical compound OC(=O)C1=CC(F)=CC=C1Cl MIZKCMSSYVUZKD-UHFFFAOYSA-N 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-N 2-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-N 0.000 description 1
- NEWMOJFYPOJQIR-UHFFFAOYSA-N 2-cyclopropylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1CC1 NEWMOJFYPOJQIR-UHFFFAOYSA-N 0.000 description 1
- NSTREUWFTAOOKS-UHFFFAOYSA-N 2-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1F NSTREUWFTAOOKS-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- HNFGGBMTWQVAED-UHFFFAOYSA-N 2-methylindazole-5-carboxylic acid Chemical compound C1=C(C(O)=O)C=CC2=NN(C)C=C21 HNFGGBMTWQVAED-UHFFFAOYSA-N 0.000 description 1
- NVLCMLWKXVOTAJ-UHFFFAOYSA-N 2-methylindazole-6-carboxylic acid Chemical compound C1=CC(C(O)=O)=CC2=NN(C)C=C21 NVLCMLWKXVOTAJ-UHFFFAOYSA-N 0.000 description 1
- CESUXLKAADQNTB-SSDOTTSWSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](N)=O CESUXLKAADQNTB-SSDOTTSWSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- VPHHJAOJUJHJKD-UHFFFAOYSA-N 3,4-dichlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C(Cl)=C1 VPHHJAOJUJHJKD-UHFFFAOYSA-N 0.000 description 1
- GONAVIHGXFBTOZ-UHFFFAOYSA-N 3,5-difluorobenzoic acid Chemical compound OC(=O)C1=CC(F)=CC(F)=C1 GONAVIHGXFBTOZ-UHFFFAOYSA-N 0.000 description 1
- SDXAWLJRERMRKF-UHFFFAOYSA-N 3,5-dimethyl-1h-pyrazole Chemical compound CC=1C=C(C)NN=1 SDXAWLJRERMRKF-UHFFFAOYSA-N 0.000 description 1
- UOKBFIOAEPCADP-UHFFFAOYSA-N 3-(hydroxymethyl)benzoic acid Chemical compound OCC1=CC=CC(C(O)=O)=C1 UOKBFIOAEPCADP-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- FCSSYEWURMTUSM-UHFFFAOYSA-N 3-chloro-2-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1F FCSSYEWURMTUSM-UHFFFAOYSA-N 0.000 description 1
- QFMRANWPGGSNHS-UHFFFAOYSA-N 3-chloro-5-fluorobenzoic acid Chemical compound OC(=O)C1=CC(F)=CC(Cl)=C1 QFMRANWPGGSNHS-UHFFFAOYSA-N 0.000 description 1
- RQRAQQYDNSRVRK-UHFFFAOYSA-N 3-cyclopropylbenzoic acid Chemical compound OC(=O)C1=CC=CC(C2CC2)=C1 RQRAQQYDNSRVRK-UHFFFAOYSA-N 0.000 description 1
- MXNBDFWNYRNIBH-UHFFFAOYSA-N 3-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC(F)=C1 MXNBDFWNYRNIBH-UHFFFAOYSA-N 0.000 description 1
- GTTKZPZHIIAOOV-UHFFFAOYSA-N 3-hydroxy-3-methylazetidine-1-carboxylic acid Chemical compound CC1(O)CN(C(O)=O)C1 GTTKZPZHIIAOOV-UHFFFAOYSA-N 0.000 description 1
- HTHMVKNHGOVITA-UHFFFAOYSA-N 3-methylazetidine Chemical compound CC1CNC1 HTHMVKNHGOVITA-UHFFFAOYSA-N 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- HYIUDFLDFSIXTR-UHFFFAOYSA-N 4,4-difluorocyclohexane-1-carboxylic acid Chemical compound OC(=O)C1CCC(F)(F)CC1 HYIUDFLDFSIXTR-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 1
- GVRRXASZZAKBMN-UHFFFAOYSA-N 4-chloroquinazoline Chemical compound C1=CC=C2C(Cl)=NC=NC2=C1 GVRRXASZZAKBMN-UHFFFAOYSA-N 0.000 description 1
- GJCRWEAWEDESNZ-UHFFFAOYSA-N 4-cyclopropylbenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1CC1 GJCRWEAWEDESNZ-UHFFFAOYSA-N 0.000 description 1
- DWUPYMSVAPQXMS-UHFFFAOYSA-N 5-bromo-1,3-thiazole Chemical compound BrC1=CN=CS1 DWUPYMSVAPQXMS-UHFFFAOYSA-N 0.000 description 1
- LPNANKDXVBMDKE-UHFFFAOYSA-N 5-bromopent-1-ene Chemical compound BrCCCC=C LPNANKDXVBMDKE-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- RDIRSUVDORCCOF-MUBNQFKJSA-N C(C)(=O)N1CC(CC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(=O)N1CC(CC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 RDIRSUVDORCCOF-MUBNQFKJSA-N 0.000 description 1
- QYQXQTPKEBMUOK-SFHVURJKSA-N C(C)(C)(C)OC(=O)ON([C@@H](CCO)C(=O)OC)CCCCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)(C)OC(=O)ON([C@@H](CCO)C(=O)OC)CCCCC1=NC=2NCCCC=2C=C1 QYQXQTPKEBMUOK-SFHVURJKSA-N 0.000 description 1
- LLJYKJQPYYHFKA-VDGAXYAQSA-N C(C)(C)(C)OC(=O)ON([C@@H](CCO)C(=O)OC)[C@@H]1C[C@H](C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)(C)OC(=O)ON([C@@H](CCO)C(=O)OC)[C@@H]1C[C@H](C1)CCC1=NC=2NCCCC=2C=C1 LLJYKJQPYYHFKA-VDGAXYAQSA-N 0.000 description 1
- HEJZDXCGIJCELV-PPSBMQLTSA-N C(C)(C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound C(C)(C)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 HEJZDXCGIJCELV-PPSBMQLTSA-N 0.000 description 1
- PDQXZMXGLYGIRI-LFNLJPBCSA-N C(C)C(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)CC Chemical compound C(C)C(C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1)CC PDQXZMXGLYGIRI-LFNLJPBCSA-N 0.000 description 1
- JODDURWFYUYUGT-IBGZPJMESA-N C(C)C(C(=O)ON([C@@H](CCO)C(=O)O)CCCCC1=NC=2NCCCC=2C=C1)CC Chemical compound C(C)C(C(=O)ON([C@@H](CCO)C(=O)O)CCCCC1=NC=2NCCCC=2C=C1)CC JODDURWFYUYUGT-IBGZPJMESA-N 0.000 description 1
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- 125000004406 C3-C8 cycloalkylene group Chemical group 0.000 description 1
- CEZCJXAOLZCCQP-YYWHXJBOSA-N CC1(CN(C1)S(=O)(=O)C)OC(=O)ON([C@@H](CCO)C(=O)OC)[C@@H]1C[C@H](C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CC1(CN(C1)S(=O)(=O)C)OC(=O)ON([C@@H](CCO)C(=O)OC)[C@@H]1C[C@H](C1)CCC1=NC=2NCCCC=2C=C1 CEZCJXAOLZCCQP-YYWHXJBOSA-N 0.000 description 1
- KJSFXFXAEBFCPL-XPTLERTKSA-N CC1=NN(C(=C1)C)C1C(CCC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound CC1=NN(C(=C1)C)C1C(CCC1)OC(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 KJSFXFXAEBFCPL-XPTLERTKSA-N 0.000 description 1
- FAOTXHNAHTVFNU-FQEVSTJZSA-N CC=1N(C(C=C(C=1C(=O)ON([C@@H](CCO)C(=O)O)CCCCC1=NC=2NCCCC=2C=C1)C)=O)CC(F)(F)F Chemical compound CC=1N(C(C=C(C=1C(=O)ON([C@@H](CCO)C(=O)O)CCCCC1=NC=2NCCCC=2C=C1)C)=O)CC(F)(F)F FAOTXHNAHTVFNU-FQEVSTJZSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- XEAZTQGMTUJPPO-JSTHURLESA-N Cl.Cl.N1=C(C=CC=2CCCNC1=2)CC[C@@H]1C[C@H](C1)OCC[C@H](N)C(=O)OC Chemical compound Cl.Cl.N1=C(C=CC=2CCCNC1=2)CC[C@@H]1C[C@H](C1)OCC[C@H](N)C(=O)OC XEAZTQGMTUJPPO-JSTHURLESA-N 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- GMEONFUTDYJSNV-UHFFFAOYSA-N Ethyl levulinate Chemical compound CCOC(=O)CCC(C)=O GMEONFUTDYJSNV-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010072877 Intestinal fibrosis Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- VPDVTEFLBYBLPH-MTQWGCILSA-N N1=C(C=CC=C1)C1(CC2(C1)CCC2)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound N1=C(C=CC=C1)C1(CC2(C1)CCC2)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 VPDVTEFLBYBLPH-MTQWGCILSA-N 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- STQFFMUUJGXUMA-FNEQHPHYSA-N O1COC2=C1C=CC(=C2)C1(CCCCC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 Chemical compound O1COC2=C1C=CC(=C2)C1(CCCCC1)C(=O)ON([C@@H](CCO)C(=O)O)C1CC(C1)CCC1=NC=2NCCCC=2C=C1 STQFFMUUJGXUMA-FNEQHPHYSA-N 0.000 description 1
- OGSHYTYJGZHOPP-STZQEDGTSA-N OCC[C@H](C(O)=O)N([C@H]1C[C@H](CCC2=NC(NCCC3)=C3C=C2)C1)OCC1=CC=NC=C1 Chemical compound OCC[C@H](C(O)=O)N([C@H]1C[C@H](CCC2=NC(NCCC3)=C3C=C2)C1)OCC1=CC=NC=C1 OGSHYTYJGZHOPP-STZQEDGTSA-N 0.000 description 1
- ZERWGBHYOAOFGK-NHCUHLMSSA-N O[C@@H](C(=O)ON([C@H](CCO)C(=O)O)CCCCC1=NC=2NCCCC=2C=C1)C1=CC=CC=C1 Chemical compound O[C@@H](C(=O)ON([C@H](CCO)C(=O)O)CCCCC1=NC=2NCCCC=2C=C1)C1=CC=CC=C1 ZERWGBHYOAOFGK-NHCUHLMSSA-N 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- VLHDTCQJXYKEJT-UHFFFAOYSA-M [Br-].CC(C)C1=CC=C([Mg+])C=C1 Chemical compound [Br-].CC(C)C1=CC=C([Mg+])C=C1 VLHDTCQJXYKEJT-UHFFFAOYSA-M 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- JYFJNCCRKBBRKZ-UHFFFAOYSA-N chembl194764 Chemical compound C=1C=CC=C(F)C=1CCN1C(=O)C(CC)=C(C)N=C1C1=CC=CC=C1O JYFJNCCRKBBRKZ-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- OBUNGSYDZFJRIU-UHFFFAOYSA-N chloromethane;n-ethylethanamine Chemical compound ClC.CCNCC OBUNGSYDZFJRIU-UHFFFAOYSA-N 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000005724 cycloalkenylene group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000004976 cyclobutylene group Chemical group 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 125000004431 deuterium atom Chemical group 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000004982 dihaloalkyl group Chemical group 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- MXWRJMIKMODSCY-UHFFFAOYSA-N ethane;dihydrochloride Chemical compound Cl.Cl.CC MXWRJMIKMODSCY-UHFFFAOYSA-N 0.000 description 1
- XGZNHFPFJRZBBT-UHFFFAOYSA-N ethanol;titanium Chemical compound [Ti].CCO.CCO.CCO.CCO XGZNHFPFJRZBBT-UHFFFAOYSA-N 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000012955 familial cardiomyopathy Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000003106 haloaryl group Chemical group 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000004254 isoquinolin-1-yl group Chemical group [H]C1=C([H])C2=C([H])C([H])=C([H])C([H])=C2C(*)=N1 0.000 description 1
- 125000004551 isoquinolin-3-yl group Chemical group C1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000000968 medical method and process Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- XOPUORAQCYGJPT-UHFFFAOYSA-N methanesulfonic acid;hydrochloride Chemical compound Cl.CS(O)(=O)=O XOPUORAQCYGJPT-UHFFFAOYSA-N 0.000 description 1
- MCVVUJPXSBQTRZ-UHFFFAOYSA-N methyl but-2-enoate Chemical compound COC(=O)C=CC MCVVUJPXSBQTRZ-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- DYGBNAYFDZEYBA-UHFFFAOYSA-N n-(cyclopropylmethyl)-2-[4-(4-methoxybenzoyl)piperidin-1-yl]-n-[(4-oxo-1,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]acetamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(CC(=O)N(CC2CC2)CC=2NC(=O)C=3COCCC=3N=2)CC1 DYGBNAYFDZEYBA-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- YGBMCLDVRUGXOV-UHFFFAOYSA-N n-[6-[6-chloro-5-[(4-fluorophenyl)sulfonylamino]pyridin-3-yl]-1,3-benzothiazol-2-yl]acetamide Chemical compound C1=C2SC(NC(=O)C)=NC2=CC=C1C(C=1)=CN=C(Cl)C=1NS(=O)(=O)C1=CC=C(F)C=C1 YGBMCLDVRUGXOV-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KCXYZMFPZHYUFO-UHFFFAOYSA-N n-methyl-n-phosphanylmethanamine Chemical compound CN(C)P KCXYZMFPZHYUFO-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 125000005574 norbornylene group Chemical group 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229940081066 picolinic acid Drugs 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- IVRIRQXJSNCSPQ-UHFFFAOYSA-N propan-2-yl carbonochloridate Chemical compound CC(C)OC(Cl)=O IVRIRQXJSNCSPQ-UHFFFAOYSA-N 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 125000004260 quinazolin-2-yl group Chemical group [H]C1=NC(*)=NC2=C1C([H])=C([H])C([H])=C2[H] 0.000 description 1
- 125000004546 quinazolin-4-yl group Chemical group N1=CN=C(C2=CC=CC=C12)* 0.000 description 1
- RAYMXZBXQCGRGX-UHFFFAOYSA-N quinoline-5-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=N1 RAYMXZBXQCGRGX-UHFFFAOYSA-N 0.000 description 1
- VXGYRCVTBHVXMZ-UHFFFAOYSA-N quinoline-6-carboxylic acid Chemical compound N1=CC=CC2=CC(C(=O)O)=CC=C21 VXGYRCVTBHVXMZ-UHFFFAOYSA-N 0.000 description 1
- WXXVQWSDMOAHHV-UHFFFAOYSA-N quinoline-7-carboxylic acid Chemical compound C1=CC=NC2=CC(C(=O)O)=CC=C21 WXXVQWSDMOAHHV-UHFFFAOYSA-N 0.000 description 1
- QRDZFPUVLYEQTA-UHFFFAOYSA-N quinoline-8-carboxylic acid Chemical compound C1=CN=C2C(C(=O)O)=CC=CC2=C1 QRDZFPUVLYEQTA-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007905 soft elastic gelatin capsule Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- LMUMMJCCZMWLEN-UHFFFAOYSA-N spiro[3.3]heptyl Chemical group [CH]1CCC11CCC1 LMUMMJCCZMWLEN-UHFFFAOYSA-N 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 150000003512 tertiary amines Chemical group 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 208000037999 tubulointerstitial fibrosis Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862742901P | 2018-10-08 | 2018-10-08 | |
| US62/742,901 | 2018-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202028179A true TW202028179A (zh) | 2020-08-01 |
Family
ID=70051340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108136254A TW202028179A (zh) | 2018-10-08 | 2019-10-07 | 胺基酸化合物及使用方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11180494B2 (enExample) |
| EP (1) | EP3863711A4 (enExample) |
| JP (1) | JP7523450B2 (enExample) |
| KR (1) | KR20210101205A (enExample) |
| CN (1) | CN113195053B (enExample) |
| AU (1) | AU2019358041A1 (enExample) |
| BR (1) | BR112021006620A2 (enExample) |
| CA (1) | CA3115643A1 (enExample) |
| CL (2) | CL2021000863A1 (enExample) |
| CO (1) | CO2021004279A2 (enExample) |
| CR (1) | CR20210224A (enExample) |
| CU (1) | CU24690B1 (enExample) |
| DO (1) | DOP2021000054A (enExample) |
| EA (1) | EA202190967A1 (enExample) |
| EC (1) | ECSP21032717A (enExample) |
| IL (1) | IL282026A (enExample) |
| JO (1) | JOP20210056A1 (enExample) |
| MX (1) | MX2021004015A (enExample) |
| PE (1) | PE20211463A1 (enExample) |
| PH (1) | PH12021550784A1 (enExample) |
| SG (1) | SG11202103283RA (enExample) |
| TW (1) | TW202028179A (enExample) |
| WO (1) | WO2020076862A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| EP4159727B1 (en) | 2017-02-28 | 2026-04-08 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| CU24684B1 (es) | 2018-03-07 | 2023-10-06 | Pliant Therapeutics Inc | Compuestos de aminoácidos como inhibidores de la integrina |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| PT3844162T (pt) | 2018-08-29 | 2025-03-28 | Morphic Therapeutic Inc | Inibidores da integrina alfa v beta6 |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| AU2019327475B2 (en) | 2018-08-29 | 2025-06-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| TW202028179A (zh) * | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| EP3952902A4 (en) | 2019-04-08 | 2022-12-21 | Pliant Therapeutics, Inc. | DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS |
| GB202010626D0 (en) | 2020-07-10 | 2020-08-26 | Univ Nottingham | Compound |
| TW202235417A (zh) | 2020-11-19 | 2022-09-16 | 美商普萊恩醫療公司 | 整合素抑制劑及其用途 |
| WO2024145245A2 (en) * | 2022-12-27 | 2024-07-04 | Pliant Therapeutics, Inc. | Alpha-v-beta-8 integrin inhibitors and uses thereof |
| GB202301024D0 (en) * | 2023-01-24 | 2023-03-08 | Univ Bradford | Compounds |
| CN122270455A (zh) * | 2023-12-22 | 2026-06-23 | 北京炫景瑞医药科技有限公司 | 一种靶向整合素αvβ6的配体、缀合物、组合物以及它们的用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| KR20100037600A (ko) | 2007-06-13 | 2010-04-09 | 브리스톨-마이어스 스큅 컴퍼니 | 응고 인자 억제제로서의 디펩티드 유사체 |
| US20120289481A1 (en) * | 2011-05-13 | 2012-11-15 | O'neil Jennifer | Compositions and methods for treating cancer |
| AU2014324426A1 (en) | 2013-09-30 | 2016-04-21 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| GB201417011D0 (en) * | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| AU2016228852A1 (en) | 2015-03-10 | 2017-10-19 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| LT3275883T (lt) | 2015-03-25 | 2021-08-25 | Fujifilm Corporation | Naujo azotą turinčio junginio arba jo druskos gamybos būdas ir jo tarpinio junginio gamyba |
| KR20190026001A (ko) | 2016-07-05 | 2019-03-12 | 더 락커펠러 유니버시티 | 테트라하이드로나프티리딘펜탄아미드 인테그린 길항물질 |
| CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
| CN110167934B (zh) | 2016-11-08 | 2022-06-10 | 百时美施贵宝公司 | 作为αV整联蛋白抑制剂的含有环丁烷和含有氮杂环丁烷的单环和螺环化合物 |
| US10696672B2 (en) | 2016-12-23 | 2020-06-30 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| EP4159727B1 (en) | 2017-02-28 | 2026-04-08 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| CU24684B1 (es) | 2018-03-07 | 2023-10-06 | Pliant Therapeutics Inc | Compuestos de aminoácidos como inhibidores de la integrina |
| US10538542B2 (en) | 2018-03-15 | 2020-01-21 | Pfizer Inc. | Cyclopentane-based modulators of STING (stimulator of interferon genes) |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| AU2019327475B2 (en) | 2018-08-29 | 2025-06-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| EP3843728B1 (en) | 2018-08-29 | 2025-04-30 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| TW202028179A (zh) * | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| EP3952902A4 (en) | 2019-04-08 | 2022-12-21 | Pliant Therapeutics, Inc. | DOSAGE FORMS AND THERAPY SCHEMES FOR AMINO ACID COMPOUNDS |
| KR20230049584A (ko) | 2020-05-07 | 2023-04-13 | 플라이언트 테라퓨틱스, 인크. | 아미노산 화합물을 사용한 호흡기 질환의 치료 |
-
2019
- 2019-10-07 TW TW108136254A patent/TW202028179A/zh unknown
- 2019-10-08 AU AU2019358041A patent/AU2019358041A1/en not_active Abandoned
- 2019-10-08 JP JP2021544112A patent/JP7523450B2/ja active Active
- 2019-10-08 SG SG11202103283RA patent/SG11202103283RA/en unknown
- 2019-10-08 CU CU2021000027A patent/CU24690B1/es unknown
- 2019-10-08 EP EP19870448.8A patent/EP3863711A4/en not_active Withdrawn
- 2019-10-08 MX MX2021004015A patent/MX2021004015A/es unknown
- 2019-10-08 CA CA3115643A patent/CA3115643A1/en active Pending
- 2019-10-08 JO JOP/2021/0056A patent/JOP20210056A1/ar unknown
- 2019-10-08 WO PCT/US2019/055252 patent/WO2020076862A1/en not_active Ceased
- 2019-10-08 PE PE2021000461A patent/PE20211463A1/es unknown
- 2019-10-08 EA EA202190967A patent/EA202190967A1/ru unknown
- 2019-10-08 BR BR112021006620A patent/BR112021006620A2/pt unknown
- 2019-10-08 CN CN201980066146.7A patent/CN113195053B/zh active Active
- 2019-10-08 CR CR20210224A patent/CR20210224A/es unknown
- 2019-10-08 US US16/596,649 patent/US11180494B2/en active Active
- 2019-10-08 KR KR1020217013781A patent/KR20210101205A/ko not_active Ceased
-
2021
- 2021-03-30 DO DO2021000054A patent/DOP2021000054A/es unknown
- 2021-04-04 IL IL282026A patent/IL282026A/en unknown
- 2021-04-07 CL CL2021000863A patent/CL2021000863A1/es unknown
- 2021-04-07 CO CONC2021/0004279A patent/CO2021004279A2/es unknown
- 2021-04-08 PH PH12021550784A patent/PH12021550784A1/en unknown
- 2021-05-07 EC ECSENADI202132717A patent/ECSP21032717A/es unknown
- 2021-10-18 US US17/504,384 patent/US11952376B2/en active Active
-
2023
- 2023-05-08 CL CL2023001331A patent/CL2023001331A1/es unknown
- 2023-12-19 US US18/545,952 patent/US20240270742A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA3115643A1 (en) | 2020-04-16 |
| CO2021004279A2 (es) | 2021-04-30 |
| AU2019358041A1 (en) | 2021-05-20 |
| US11952376B2 (en) | 2024-04-09 |
| US20200109141A1 (en) | 2020-04-09 |
| CL2021000863A1 (es) | 2021-09-10 |
| CN113195053B (zh) | 2024-08-30 |
| PH12021550784A1 (en) | 2021-10-25 |
| US20220144829A1 (en) | 2022-05-12 |
| EP3863711A4 (en) | 2022-07-06 |
| EP3863711A1 (en) | 2021-08-18 |
| CN113195053A (zh) | 2021-07-30 |
| SG11202103283RA (en) | 2021-04-29 |
| DOP2021000054A (es) | 2021-08-31 |
| MX2021004015A (es) | 2021-06-23 |
| IL282026A (en) | 2021-05-31 |
| WO2020076862A1 (en) | 2020-04-16 |
| JOP20210056A1 (ar) | 2021-03-24 |
| CL2023001331A1 (es) | 2023-10-20 |
| ECSP21032717A (es) | 2021-06-30 |
| KR20210101205A (ko) | 2021-08-18 |
| CU20210027A7 (es) | 2021-11-04 |
| JP7523450B2 (ja) | 2024-07-26 |
| US20240270742A1 (en) | 2024-08-15 |
| BR112021006620A2 (pt) | 2021-07-06 |
| EA202190967A1 (ru) | 2021-09-17 |
| JP2022508657A (ja) | 2022-01-19 |
| PE20211463A1 (es) | 2021-08-05 |
| CR20210224A (es) | 2021-06-08 |
| US11180494B2 (en) | 2021-11-23 |
| CU24690B1 (es) | 2023-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7523450B2 (ja) | アミノ酸化合物およびその使用方法 | |
| TWI841573B (zh) | 具有未分支連接子之胺基酸化合物及使用方法 | |
| AU2018392321B2 (en) | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists | |
| JP7271557B2 (ja) | Ｉｌ－１７モジュレータとしての縮合イミダゾール誘導体 | |
| ES3058680T3 (en) | Cyclohexyl acid isoxazole azines as lpa antagonists | |
| ES2938863T3 (es) | Triazol azoles de ácido ciclohexilo como antagonistas de ácido lisofosfatídico (LPA) | |
| JP2024519496A (ja) | ブルトンのチロシンキナーゼの分解を標的化するための化合物 | |
| TW202204340A (zh) | Lpa受體拮抗劑及其用途 | |
| CA3042710A1 (en) | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as .alpha.v integrin inhibitors | |
| US20150210640A1 (en) | 1-(cycloalkyl-carbonyl)proline derivative | |
| TW201040166A (en) | Isoxazol-3(2H)-one analogs as therapeutic agents | |
| JP2022500470A (ja) | Ｌｐａアンタゴニストとしてのシクロペンチル酸 | |
| CN114728958A (zh) | Rip1抑制性化合物和制备与使用其的方法 | |
| BR122023025996A2 (pt) | Compostos de aminoácidos, composição farmacêutica e kit compreendendo os mesmos, seus usos, e seu método de produção | |
| HK40057175A (en) | Amino acid compounds and methods of use | |
| HK40049583A (en) | Amino acid compounds with unbranched linkers and methods of use | |
| TW202542145A (zh) | Smyd調節劑及其用途 | |
| NZ750013A (en) | Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists |